Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Concerning FOLFOX + Nivolumab & Gastric Cancer / Gastric adenocarcinoma / Stomach cancer, in April 2021, the FDA approved nivolumab in combination with fluoropyrimidine‑ and platinum‑containing chemotherapy for first‑line treatment of advanced or metastatic HER2‑negative Gastric Cancer / Gastric adenocarcinoma / Stomach cancer, GEJ based on CheckMate‑649. The FDA label is not limited to a particular oxaliplatin regimen; it allows standard fluoropyrimidine‑platinum backbones (e.g., FOLFOX or CAPOX), so FOLFOX + nivolumab fits within the approved “nivolu…